Previous Close | 4,294.00 |
Open | 4,310.00 |
Bid | 4,202.00 x 0 |
Ask | 4,207.00 x 0 |
Day's Range | 4,201.00 - 4,313.00 |
52 Week Range | 3,900.00 - 4,873.00 |
Volume | |
Avg. Volume | 4,658,505 |
Market Cap | 6.594T |
Beta (5Y Monthly) | 0.54 |
PE Ratio (TTM) | 37.42 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 188.00 (4.28%) |
Ex-Dividend Date | Mar 28, 2024 |
1y Target Est | N/A |
OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.
Seemingly small changes by policy makers and companies remade Japan’s corporate culture, and investors are cashing in.
Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).